The systemic amyloidoses

New England Journal of Medicine

Volumn 337, Issue 13, 1997, Pages 898-909

  Falk, Rodney H ^a,b   Comenzo, Raymond L ^a   Skinner, Martha ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; MELPHALAN;

ALGORITHM; AMYLOIDOSIS; ARTICLE; CLINICAL EXAMINATION; DISEASE CLASSIFICATION; FAMILIAL DISEASE; HUMAN; LIVER TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS;

AMYLOIDOSIS; HUMANS; PROGNOSIS;

EID: 0030954873     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199709253371306     Document Type: Article

References (94)

1. Virchow VR. Ueber einem Gehirn and Rueckenmark des Menschen auf gefundene Substanz mit chemischen reaction der Cellulose. Virchows Arch Pathol Anat 1854;6:135-8.
2. Bennhold H. Eine spezifische Amyloidfärbung mit Kongorot. Munch Med Wochenschr 1922;69:1537-8.
3. Divry P, Florkin M. Sur les propriétés optiques de l'amyloïde. C R Seances Soc Biol 1927;97:1808-10.
4. Cohen AS, Calkins E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 1959;183:1202-3.
5. Shirahama T, Cohen AS. High resolution electron microscopic analysis of the amyloid fibril. J Cell Biol 1967;33:679-708.
6. Bonar L, Cohen AS, Skinner MM. Characterization of the amyloid fibril as a cross-beta protein. Proc Soc Exp Biol Med 1969;131:1373-5.
7. Glenner GG, Terry W, Harada M, Isersky C, Page D. Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses. Science 1971;172:1150-1.
8. Benditt EP, Eriksen N, Hermodson MA, Ericsson LH. The major proteins of human and monkey amyloid substance: common properties including unusual N-terminal amino acid sequences. FEBS Lett 1971;19: 169-73.
9. Costa PP, Figueira AS, Bravo FR. Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci U S A 1978;75:4499-503.
10. WHO-IUIS Nomenclature Sub-Committee. Nomenclature of amyloid and amyloidosis. Bull World Health Organ 1993;71:105-12.
11. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmstead County, Minnesota, 1950 through 1989. Blood 1992;79:1817-22.
12. Jacobson DR, Pastore R, Pool S, et al. Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 1996;98:236-8.
13. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997;336:466-73.
14. Bellotti V, Merlini G, Bucciarelli E, Perfetti V, Quaglini S, Ascari E. Relevance of class, molecular weight and isoelectric point in predicting human light chain amyloidogenicity. Br J Haematol 1990;74:65-9.
15. Hurle MR, Helms LR, Li L, Chan W, Wetzel R. A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci U S A 1994;91:5446-50.
16. Blake CCF, Geisow MJ, Oatley SJ, Rérat B, Rérat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1·8 Å. J Mol Biol 1978;121:339-56.
17. McCutchen SL, Colon W, Kelly JW. Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry 1993;32:12119-27.
18. Westermark P, Sletten K, Johansson B, Cornwell GG III. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A 1990;87:2843-5.
19. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993;32: 4693-7.
20. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
21. Solomon A, Frangione B, Franklin EC. Bence Jones proteins and light chains of immunoglobulins: preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda). J Clin Invest 1982;70:453-60.
22. Liepnieks JJ, Benson MD, Dwulet FE. Comparison of the amino acid sequences often kappa I amyloid proteins for amyloidogenic sequences. In: Natvig JB, Førre Ø, Husby G, et al., eds. Amyloid and amyloidosis 1990. Dordrecht, the Netherlands: Kluwer Academic, 1991:153-6.
23. Stevens FJ, Myatt EA, Chang C-H, et al. A molecular model for self-assembly of amyloid fibrils: immunoglobulin light chains. Biochemistry 1995;34:10697-702.
24. Billadeau D, Van Ness B, Kimlinger T, et al. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood 1996;88:289-96.
25. Benson MD. Amyloidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 7th ed. Vol. 3. New York: McGraw-Hill, 1995:4159-91.
26. Nichols WC, Dwulet FE, Liepnieks J, Benson MD. Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. Biochem Biophys Res Commun 1988;156:762-8.
27. Maury CPJ, Kere J, Tolvanen R, de la Chapelle A. Finnish hereditary amyloidosis is caused by a single nucleotide substitution in the gelsolin gene. FEBS Lett 1990;276:75-7.
28. Benson MD, Leipnieks J, Uemichi T, Wheeler G, Correa R. Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain. Nat Genet 1993;3:252-5.
29. Pepys MB, Hawkins PN, Booth DR, et al. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 1993;362:553-7.
30. Costa RH, Grayson DR, Darnell JE Jr. Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes. Mol Cell Biol 1989;9:1415-25.
31. Dickson PW, Schreiber G. High levels of messenger RNA for transthyretin (prealbumin) in human choroid plexus. Neurosci Lett 1986;66: 311-5.
32. Tawara S, Nakazato M, Kangawa K, Matsuo H, Araki S. Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type). Biochem Biophys Res Commun 1983;116:880-8.
33. Saraiva MJM, Birken S, Costa PP, Goodman DS. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type: definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 1984;74: 104-19.
34. Wallace MR, Dwulet FE, Conneally PM, Benson MD. Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis. J Clin Invest 1986;78:6-12.
35. Nichols WC, Liepnieks JJ, Snyder EL, Benson MD. Senile cardiac amyloidosis associated with homozygosity for a transthyretin variant (ILE 122). J Lab Clin Med 1991;117:175-80.
36. Saraiva MJM, Sherman W, Marboe C, et al. Cardiac amyloidosis: report of a patient heterozygous for the transthyretin isoleucine 122 variant. Scand J Immunol 1990;32:341-6.
37. Jacobson DR, Gorevic PD, Buxbaum JN. A homozygous transthyretin variant associated with senile systemic amyloidosis: evidence for a late-onset disease of genetic etiology. Am J Hum Genet 1990;47:127-36.
38. Jacobson DR, Buxbaum JN. Genetic aspects of amyloidosis. Adv Hum Genet 1991;20:69-123.
39. Holmgren G, Holmberg E, Lindstrom A, et al. Diagnosis of familial amyloidotic polyneuropathy in Sweden by RFLP analysis. Clin Genet 1988;33:176-80.
40. Skare J, Yazici H, Erken E, et al. Homozygosity for the met30 transthyretin gene in a Turkish kindred with familial amyloidotic polyneuropathy. Hum Genet 1990;86:89-90.
41. McAdam KPWJ, Sipe JD. Murine model for human secondary amyloidosis: genetic variability of the acute-phase serum protein SAA response to endotoxins and casein. J Exp Med 1976;144:1121-7.
42. Kluve-Beckerman B, Dwulet FE, Benson MD. Human serum amyloid A: three hepatic mRNAs and the corresponding proteins in one person. J Clin Invest 1988;82:1670-5.
43. Faulkes DJ, Betts JC, Woo P. Characterization of five human serum amyloid A1 alleles. Amyloid Int J Exp Clin Invest 1994;1:255-62.
44. Husby G. Amyloidosis and rheumatoid arthritis. Clin Exp Rheumatol 1985;3:173-80.
45. Cueto-Garcia L, Reeder GS, Kyle RA, et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol 1985;6:737-43.
46. Falk RH, Plehn JF, Deering T, et al. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol 1987;59: 418-22.
47. Klein AL, Hatle LK, Burstow DJ, et al. Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1989;13:1017-26.
48. Dubrey S, Pollak A, Skinner M, Falk RH. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J 1995;74:541-4.
49. Gertz MA, Falk RH, Skinner M, Cohen AS, Kyle RA. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol 1985;55:1645.
50. Carlson HC, Breen JF. Amyloidosis and plasma cell dyscrasias: gastrointestinal involvement. Semin Roentgenol 1986;21:128-38.
51. Tada S, Iida M, Yao T, Kitamoto T, Yao T, Fujishima M. Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein. Gut 1993;34:1412-7.
52. Rubinow A, Koff RS, Cohen AS. Severe intrahepatic cholestasis in primary amyloidosis: a report of four cases and a review of the literature. Am J Med 1978;64:937-46.
53. Gertz MA, Kyle RA, Greipp PR. Hyposplenism in primary systemic amyloidosis. Ann Intern Med 1983;98:475-7.
54. Skinner M, Talarico L, Cohen AS, St John A. The calcium-dependent interaction of blood clotting factors with primary amyloid fibrils. In: Glenner GG, Costa PP, de Freitas AF, eds. Amyloid and amyloidosis. No. 497 of International congress series. Amsterdam: Excerpta Medica, 1980:361-5.
55. Yood RA, Skinner M, Rubinow A, Talarico L, Cohen AS. Bleeding manifestations in 100 patients with amyloidosis. JAMA 1983;249:1322-4.
56. Skinner M, Anderson JJ, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996;100:290-8.
57. Marinone MG, Marinone MG, Merlini G. Reduced taste perception in AL amyloidosis: a frequently unnoticed sensory impairment. Haematologica 1996;81:110-5.
58. Smith RR, Hutchins GM, Moore GW, Humphrey RL. Type and distribution of pulmonary parenchymal and vascular amyloid: correlation with cardiac amyloid. Am J Med 1979;66:96-104.
59. Utz JP, Swensen SJ, Gertz MA. Pulmonary amyloidosis: the Mayo Clinic experience from 1980 to 1993. Ann Intern Med 1996;124:407-13.
60. Danby P, Harris KPG, Williams B, Feehally J, Walls J. Adrenal dysfunction in patients with renal amyloid. Q J Med 1990;76:915-22.
61. Gertz MA, Kyle RA. Secondary systemic amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 1991;70:246-56.
62. Dubrey SW, Cha K, Simms RW, Skinner M, Falk RH. Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol 1996;77:313-5.
63. Libbey CA, Skinner M, Cohen AS. Use of abdominal fat tissue aspirate in the diagnosis of systemic amyloidosis. Arch Intern Med 1983;143:1549-52.
64. Duston MA, Skinner M, Shirahama T, Cohen AS. Diagnosis of amyloidosis by abdominal fat aspiration: analysis of four years' experience. Am J Med 1987;82:412-4.
65. Altland K, Banzhoff A. Separation by hybrid isoelectric focusing of normal human plasma transthyretin (prealbumin) and a variant with a methionine for valine substitution associated with familial amyloidotic polyneuropathy. Electrophoresis 1986;7:529-33.
66. Kyle RA, Spittell PC, Gertz MA, et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med 1996;101: 395-400.
67. Shirahama T, Cohen AS, Skinner M. Immunohistochemistry of amyloid. In: DeLellis RA, ed. Advances in immunohistochemistry. New York: Masson, 1984:277-302.
68. Falk RH, Lee VW, Rubinow A, Skinner M, Cohen AS. Cardiac technetium-99m pyrophosphate scintigraphy in familial amyloidosis. Am J Cardiol 1984;54:1150-1.
69. Aprile C, Marinone G, Saponaro R, Bonino C, Merlini G. Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin. Eur J Nucl Med 1995;22:1393-401.
70. 123I-labeled serum amyloid P component. N Engl J Med 1990;323:508-13.
71. Skinner M. Amyloidosis. In: Lichtenstein LM, Fauci AS, eds. Current therapy in allergy, immunology, and rheumatology. 5th ed. St. Louis: Mosby-Year Book, 1996:235-40.
72. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981;63:1285-8.
73. Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Ailing DW. Colchicine therapy for familial Mediterranean fever: a double-blind trial. N Engl J Med 1974;291:934-7.
74. Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 1986;314:1001-5.
75. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-7.
76. Dubrey SW, Mendes L, Skinner M, Falk RH. Resolution of heart failure in patients with AL amyloidosis. Ann Intern Med 1996;125:481-4.
77. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991;77:257-62.
78. Comenzo RL, Vosburgh E, Simms RW, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996;88:2801-6.
79. Comenzo RL, Sarnacki D, Finn K, et al. AL amyloidosis responds to high-dose melphalan and blood stem cells. Blood 1996;88:Suppl 1:686a. abstract.
80. Moreau P, Milpied N, de Faucal P, et al. High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement. Blood 1996;87:3063-4.
81. van Buren M, Hene RJ, Verdonck LF, Verzijlbergen FJ, Lokhorst HM. Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis. Ann Intern Med 1995;122:508-10.
82. Hosenpud JD, DeMarco T, Frazier OH, et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation: follow-up results of a multicenter survey. Circulation 1991;84:SupPl III:III-338-III-343.
83. Hall R, Hawkins PN. Cardiac transplantation for AL amyloidosis. BMJ 1994;309:1135-7.
84. Dubrey S, Falk RH. Heart transplantation in AL amyloidosis. Amyloid Int J Exp Clin Invest 1995;2:284-7.
85. Gianni L, Bellotti V, Gianni AM, Merlini G. New drug therapy of amyloidosis: resorption of AL-type deposits with 4′-iodo-4′-deoxydoxorubicin. Blood 1995;86:855-61.
86. Merlini G, Ascari E, Amboldi N, et al. Interaction of the anthracycline 4′-iodo-4′-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis. Proc Natl Acad Sci U S A 1995;92:2959-63.
87. Holmgren G, Steen L, Ekstedt J, et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet 1991;40:242-6.
88. Lewis WD, Skinner M, Simms RW, Jones LA, Cohen AS, Jenkins RL. Orthotopic liver transplantation for familial amyloidotic polyneuropathy. Clin Transplant 1994;8:107-10.
89. Holmgren G, Ericzon B-G, Groth C-G, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993;341:1113-6.
90. Skinner M, Lewis WD, Jones LA, et al. Liver transplantation as a treatment for familial amyloidotic polyneuropathy. Ann Intern Med 1994;120: 133-4.
91. Steen L, Holmgren G, Suhr O, Wikstrom L, Ericzon B-G, Groth C-G. World-wide survey of liver transplantations in patients with familial amyloidotic polyneuropathy. Amyloid Int J Exp Clin Invest 1994;1:138-42.
92. Bergethon PR, Sabin TD, Lewis D, Simms RW, Cohen AS, Skinner M. Improvement in the polyneuropathy associated with familial amyloid polyneuropathy after liver transplantation. Neurology 1996;47:944-51.
93. Ericzon B-G. Liver transplantation for familial amyloid polyneuropathy - report from the World Registry. Neuromuscul Disord 1996;6:Suppl: S65. abstract.
94. Casey RP. Fighting for life. Dallas: Word Publishing, 1996.